Skip to content
Dx

ICD-10-CM 2027 diagnosis code

D61.82Myelophthisis

✓ Billable / specificCC — complication/comorbidity

D61.82 is a valid, billable ICD-10-CM code for myelophthisis. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Looking up by condition? See ICD-10 code for Myelophthisis, ICD-10 code for Panmyelophthisis.

Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About D61.82

D61.82 is the ICD-10-CM diagnosis code for Myelophthisis. It belongs to category D61 (other aplastic anemias and other bone marrow failure syndromes), block D60-D64 (aplastic and other anemias and other bone marrow failure syndromes) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D61.8 (other specified aplastic anemias and other bone marrow failure syndromes), D61.82 is specifically for Myelophthisis. Related codes cover pancytopenia (D61.81) and other specified aplastic anemias and other bone marrow failure syndromes (D61.89).

Don't report D61.82 together with the conditions in its Excludes1 note: idiopathic myelofibrosis (D47.1), myelofibrosis NOS (D75.81), myelofibrosis with myeloid metaplasia (D47.4), primary myelofibrosis (D47.1) and 1 more.

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC, relative weight 6.2481), DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC, relative weight 2.2023), DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC, relative weight 1.1272), DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC, relative weight 4.6059), DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC, relative weight 2.2515), DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC, relative weight 1.2995) and 3 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 284.2 (Myelophthisis).

Coding notes

Applicable toConditions and synonyms classified to this code
  • Leukoerythroblastic anemia
  • Myelophthisic anemia
  • Panmyelophthisis
Excludes1Not coded here — never report together with this code
  • idiopathic myelofibrosis (D47.1)
  • myelofibrosis NOS (D75.81)
  • myelofibrosis with myeloid metaplasia (D47.4)
  • primary myelofibrosis (D47.1)
  • secondary myelofibrosis (D75.81)
Code alsoTwo codes may be needed; sequencing depends on circumstances
  • the underlying disorder, such as:
  • malignant neoplasm of breast (C50.-)
  • tuberculosis (A15.-)

Notes that apply from higher levels

Instructions written at a parent level also apply to D61.82.

› From D61 Other aplastic anemias and other bone marrow failure syndromes
Excludes2
  • neutropenia (D70.-)

Broader instructions also apply from Chapter 3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.

Alphabetic index entries

5 entries

Terms in the official ICD-10-CM index that lead to D61.82.

Codes whose notes reference D61.82

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

ICD-9-CM equivalent

Converter →

From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
  • No changes since FY2016.

Common questions about D61.82

Is D61.82 billable?

Yes. D61.82 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can D61.82 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict D61.82 as a principal diagnosis.

Is D61.82 a CC or MCC?

D61.82 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.

What DRG does D61.82 group to?

D61.82 is used in the MS-DRG v44.0 logic for MS-DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC), MS-DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC), MS-DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC), MS-DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC), MS-DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC), MS-DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC) and 3 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.

What is the ICD-9 code for D61.82?

The CMS General Equivalence Mappings map D61.82 to ICD-9-CM 284.2.